Randomized Prospective Evaluation of Microblepharoexfoliation BlephEx as Adjunctive Therapy in the Treatment of Chalazia.
Journal
Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186
Informations de publication
Date de publication:
01 Feb 2023
01 Feb 2023
Historique:
received:
27
10
2021
accepted:
16
05
2022
pubmed:
23
7
2022
medline:
3
1
2023
entrez:
22
7
2022
Statut:
ppublish
Résumé
Chalazia are benign eyelid lesions caused by the obstruction and inflammatory reaction of the meibomian glands. Demodex mites are one potential cause of chalazia leading to mechanical obstruction of the meibomian gland. In this prospective randomized study, we examine a novel approach to treating chalazia with the use of microblepharoexfoliation (MBE), an in-office lid hygiene technique that exfoliates the eyelid margins. Fifty patients with clinical evidence of acute chalazion were enrolled in this study. Subjects were randomly assigned to a MBE plus lid hygiene group (23 patients, mean age 66.6 ± 16.6 years) or a lid hygiene alone group (27 patients, mean age 62.1 ± 14.4). The MBE plus lid hygiene group received MBE treatment and were evaluated 1 month after the baseline visit. The main outcome measured was the resolution of the chalazion at the 1-month follow-up visit. The lid hygiene plus MBE treatment group demonstrated a statistically significant resolution of the chalazion compared with the lid hygiene group alone ( P = 0.007; chi-square test). Among the MBE plus hygiene group, 87% of the patients had resolution of their chalazion as opposed to the lid hygiene alone group, which had 44% resolution. This is the first prospective, randomized clinical trial that demonstrated efficacy of MBE as a noninvasive adjunctive treatment method for chalazion resolution.
Identifiants
pubmed: 35867627
doi: 10.1097/ICO.0000000000003090
pii: 00003226-202302000-00007
pmc: PMC9797196
doi:
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
172-175Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
H. D. Perry, MD, serves as a consultant for BlephEx. The remaining authors have no conflicts of interest to disclose.
Références
Perry HD, Serniuk RA. Conservative treatment of chalazia. Ophthalmology. 1980;87:218–221.
Das AV, Dave TV. Demography and clinical features of chalazion among patients seen at a multi-tier eye care network in India: an electronic medical records driven big data analysis report. Clin Ophthalmol. 2020;14:2163–2168.
Arbabi EM, Kelly RJ, Carrim ZI. Chalazion. BMJ. 2010;341:c404.
Wu AY, Gervasio KA, Gergoudis KN, et al. Conservative therapy for chalazia: is it really effective? Acta Ophthalmol (Copenh) 2018;96:e503–e509.
Alsoudi AF, Ton L, Ashraf DC, et al. Efficacy of care and antibiotic use for chalazia and hordeola. Eye Contact Lens 2022;48:162–168.
Korb DR, Blackie CA. Meibomian gland therapeutic expression: quantifying the applied pressure and the limitation of resulting pain, Eye Contact Lens. 2011;37:298–301.
Liu J, Sheha H, Tseng SCG. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010;10:505–510.
Yam JCS, Tang BSF, Chan TM, et al. Ocular demodicidosis as a risk factor of adult recurrent chalazion. Eur J Ophthalmol. 2014;24:159–163.
Liang L, Ding X, Tseng SCG. High prevalence of Demodex brevis infestation in chalazia. Am J Ophthalmol. 2014;157:342–348.e1.
Fromstein SR, Harthan JS, Patel J, et al. Demodex blepharitis: clinical perspectives. Clin Optom. 2018;10:57–63.
Schear MJ, Milman T, Steiner T, et al. The association of Demodex with chalazia: a histopathologic study of the eyelid. Ophthal Plast Reconstr Surg. 2016;32:275–278.
Murphy O, O'Dwyer V, Lloyd-McKernan A. The efficacy of tea tree face wash, 1, 2-Octanediol and microblepharoexfoliation in treating Demodex folliculorum blepharitis. Contact Lens Anterior Eye. 2018;41:77–82.
Epstein IJ, Rosenberg E, Stuber R, et al. Double-masked and unmasked prospective study of terpinen-4-ol lid scrubs with microblepharoexfoliation for the treatment of Demodex blepharitis. Cornea. 2020;39:408–416.
Choi MiB, Stein R, Perry HD. Lid hygiene versus lid hygiene plus microblepharoexfoliation for the treatment of Demodex folliculorum blepharitis. Acta Sci Ophthalmol. 2020;3:29–35.
Efird J. Blocked randomization with randomly selected block sizes. Int J Environ Res Public Health. 2011;8:15–20.
Romero JM, Biser SA, Perry HD, et al. Conservative treatment of meibomian gland dysfunction. Eye Contact Lens 2004;30:14–19.
Miller KL, Walt JG, Mink DR, et al. Minimal clinically important difference for the ocular surface disease index. Arch Ophthalmol. 2010;128:94–101.
Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118:615–621.
Pepose JS, Sullivan BD, Foulks GN, et al. The value of tear osmolarity as a metric in evaluating the response to dry eye therapy in the clinic and in clinical trials. Am J Ophthalmol. 2014;157:4–6.e1.
Chotikavanich S, de Paiva CS, Li DQ, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci. 2009;50:3203–3209.
Lamberts DW, Foster CS, Perry HD. Schirmer test after topical anesthesia and the tear meniscus height in normal eyes. Arch Ophthalmol. 1979;97:1082–1085.
Pizzarello LD, Jakobiec FA, Hofeldt AJ, et al. Intralesional corticosteroid therapy of chalazia. Am J Ophthalmol. 1978;85:818–821.
Ben Simon GJ, Rosen N, Rosner M, et al. Intralesional triamcinolone acetonide injection versus incision and curettage for primary chalazia: a prospective, randomized study. Am J Ophthalmol. 2011;151:714–718.e1.
Aycinena ARP, Achiron A, Paul M, et al. Incision and curettage versus steroid injection for the treatment of chalazia: a meta-analysis. Ophthal Plast Reconstr Surg. 2016;32:220–224.